Novel drug approval by the FDA - Ekterly(Sebetralstat), oral plasma kallikrein inhibitor for treating acute attacks of hereditary angioedema

Sep 29, 2026

Uploaded by kopisore

Hereditary angioedema (HAE) is a challenging, potentially life-threatening disorder caused by dysregulated plasma kallikrein activity and excessive bradykinin generation. Many acute-attack treatments depend on injectable or intravenous delivery, which can delay care in low-resource or emergency-limited settings. FDA approval of Ekterly (sebetralstat), the first oral plasma kallikrein inhibitor for acute HAE attacks in patients aged 12+, marks a major management shift. This editorial explains the scientific rationale, reviews KONFIDENT trial results, and evaluates safety, efficacy, and clinical fit, highlighting faster onset and oral independence. It also discusses CYP3A4 interactions and limited evidence in pregnancy or hepatic impairment.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages3

Reading Time8 min

AccessFree to download

Abstract

Dear Editor

Background on hereditary angioedema (HAE)

C1-INH regulation and bradykinin mechanism

Current treatment options for HAE with C1-inhibitor deficiency

Editorial Novel drug approval by the FDA: Ekterly(Sebetralstat), oral plasma kallikrein inhibitor fortreating acute attacks of hereditary angioedema Gulalai, BDSa , Syeda Aiman Miraj, MBBSb , Raghabendra Kumar Mahato, MBBSc ,* # Abstract Hereditary angioedema (HAE) remains a challenging, potentially life-threatening disorder driven by dysregulated plasma kallikreinactivity and excessive bradykinin generation. Despite major therapeutic advances, most available treatments for acute attacks relyon injectable or intravenous agents that impose barriers to timely administration, particularly in low-resource or emergency-limitedsettings. The recent FDA approval of Ekterly (sebetralstat), the first orally administered plasma kallikrein inhibitor for acute HAEattacks inpatients aged 12 years and older, represents a landmark shift in the management of this rare disorder. In this editorial, wehighlight the scientific rationale behind sebetralstat, summarize key findings from the KONFIDENT clinical trial, and evaluate itssafety, efficacy, and clinical applicability. Ekterly demonstrated a significantly faster onset of symptom relief, earlier reduction inattack severity, and more rapid attack resolution compared with placebo, marking a meaningful improvement over existingtherapies. Its oral administration represents a significant therapeutic advancement, allowing patients to manage acute attackspromptly and independently without reliance on clinical facilities. This is particularly advantageous in settings with limited access tointravenous therapy, cold-chain storage, or timely emergency care. The novelty of our work lies in synthesizing emergingmechanistic insights, regulatory developments, real-world applicability, and clinical trial performance into a unified evaluation of thefirst oral short-term prophylactic and on-demand kallikrein inhibitor for HAE. Through a detailed appraisal of its therapeutic efficacy,safety profile, and pharmacologic constraints -including clinically relevant interactions with CYP3A4 modulators andthe lack ofevidence in pregnant patients or those with hepatic impairment,this editorial emphasizes Ekterly’semerging role as an importantand potentially transformative addition to HAE management.The approval of sebetralstat signals a new era of convenient, rapid -acting, accessible treatment for HAE, with the potential to reduce emergency visits, enhance patient autonomy, and improvequality of life. Continued surveillance, long-term safety studies, and global access initiatives will be essential to maximize its public -health impact and ensure equitable availability of this breakthrough oral therapy. Keywords: Bradykinin, CYP3A4, Ekterly, hereditary angioedema, Sebetralstat Dear Editor, Hereditary angioedema (HAE) is a rare genetic disorderinherited in an autosomal dominant pattern, resulting frommutations in the gene responsible for producing C1 esteraseinhibitor (C1-INH). This protein plays a critical regulatory role aDepartment of Dentistry, Bacha Khan College of Dentistry, Mardan, Pakistan,bDepartment of Medicine, Khyber Medical College, Peshawar, Pakistan andcDepartment of Medicine, Gandaki medical College Teaching Hospital andResearch Center, Pokhara Nepal Sponsorships or competing interests that maybe relevant to content are disclosedatthe end of this article. *Corresponding author. Address: Department of Medicine, Gandaki MedicalCollege Teaching Hospital and Research Center, Pokhara 33700, Nepal.Tel.: +977-9745829807. E-mail: raghabendra.mahato2024@gmcthrc.edu.np(R.K. Mahato). Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc. This is anopen access article distributed under the terms of the Creative CommonsAttribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where itispermissible to download and share the work provided itis properly cited. The workcannot be changed in any way or used commercially without permission from thejournal. Annals of Medicine

FAQs

What problem does Ekterly (sebetralstat) address in acute hereditary angioedema attacks?

It targets dysregulated plasma kallikrein activity to reduce bradykinin-driven swelling. As an oral option, it aims to deliver symptom relief faster and remove barriers of injectable or intravenous therapy, especially where emergency resources are limited.

What evidence from the KONFIDENT clinical trial is emphasized?

The editorial highlights significantly faster onset of symptom relief, earlier reduction in attack severity, and more rapid resolution compared with placebo.

What safety or clinical-eligibility considerations are mentioned?

The editorial notes clinically relevant interactions with CYP3A4 modulators and states that evidence is lacking for pregnant patients or those with hepatic impairment.

Sep 29, 2026

Uploaded by kopisore